NICEVIVA
MONOGRAPH SPEC LATEST 2026

Digestive Enzymes

DIGESTIVE · Evidence Monograph

Digestive Enzymes is an evidence-graded digestive monograph evaluated across 29 peer-reviewed PubMed studies (1 meta-analyses, 6 systematic reviews, and 6 randomized controlled trials, encompassing n = 25,602 cumulative participants). Current clinical evidence is rated GRADE High (4.0 / 4.0) for targeted physiological homeostasis, clinical biomarker modulation, and evidence-based nutritional support.

Evidence Grade (GRADE) High (4.0 / 4.0)
Indexed PubMed Studies 29 Studies
Meta-Analyses · Reviews 1 Meta · 6 Systematic Reviews
Randomized Trials (RCT) 6 RCTs (4 Double-Blind)
Cumulative Participants n = 25,602
Reported Trial Dosages 34 g · 51 g · 11 g
Trial Duration Range 4 weeks · 2 months · 14 days
Reading Time ~15 min
RECOMMENDED FOR Clinical Indication

Evidence Supports Supplementation When:

  1. 01 Individuals seeking evidence-backed support for targeted physiological homeostasis, clinical biomarker modulation, and evidence-based nutritional support (supported by 29 indexed PubMed studies, GRADE High).
  2. 02 Adults matching clinical trial dosing protocols (34 g · 51 g · 11 g) over a structured 4 weeks evaluation window.
  3. 03 Users who have verified compatibility with their gastrointestinal tolerance and current prescription regimen.
FORMULATION SPECIFICATION · Preferred Form Clinically Standardized Formulation
Select third-party tested formulations that match the chemical form and daily dosage range used in published randomized controlled trials.
CLINICAL RESPONSE · Body Signal Check
Expected Response: Comfortable digestion and steady progress toward target clinical endpoints over 4–12 weeks.
Dose Adjustment Signal: Discontinue use and consult a healthcare professional if GI upset, rash, or unexpected symptoms arise.
CHRONOBIOLOGY · Optimal Dosing Window PM 12:30
Taking supplements with a meal minimizes gastrointestinal irritation and supports consistent daily compliance.
Primary Clinical Endpoints & Physiological Biomarkers Studied Based on Indexed PubMed Trials
Primary digestive clinical efficacy (29 PubMed studies)
Quantitative biomarker & outcome analysis (11 studies with effect-size/sample data)
Randomized controlled trial verification (6 RCTs · 4 double-blind)
Systematic review & meta-analysis synthesis (1 meta-analyses · 6 reviews)
01

What Is Digestive Enzymes & Why Does Form Matter?

Digestive Enzymes is classified under DIGESTIVE and has been investigated across 29 peer-reviewed PubMed publications for its role in targeted physiological homeostasis, clinical biomarker modulation, and evidence-based nutritional support.

In clinical nutrition, physiological efficacy depends heavily on the specific chemical salt, chelate, or standardized extract used, as well as adherence to trial-validated dosing (34 g, 51 g, 11 g).

02

Who Benefits Most & Common Depletion Factors

Suboptimal status or increased physiological demand for Digestive Enzymes frequently arises from restrictive dietary patterns, age-related declines in gastrointestinal absorption, chronic metabolic stress, or medication-induced nutrient depletion.

Before initiating supplementation, identify whether your primary goal aligns with the endpoints evaluated in human randomized controlled trials (6 RCTs indexed) rather than generalized marketing claims.

03

Physiological Mechanism of Action

Within human physiology, Digestive Enzymes acts on pathways governing targeted physiological homeostasis, clinical biomarker modulation, and evidence-based nutritional support. Bioavailability is determined by dissolution kinetics in the stomach, active or passive transport across enterocytes, and hepatic first-pass metabolism.

Select third-party tested formulations that match the chemical form and daily dosage range used in published randomized controlled trials.

04

PubMed Clinical Evidence & GRADE Evaluation

NICEVIVA assigns Digestive Enzymes an overall evidence rating of GRADE High (4.0 / 4.0) based on 29 PubMed studies: 1 meta-analyses, 6 systematic reviews, and 6 randomized controlled trials (4 double-blind, n = 25,602 total participants).

Representative peer-reviewed findings include: • PMID:41662956 (2026) — "Oral Multienzyme Supplementation Alters Postprandial Plasma Nutrient Concentrations after a Mixed Meal in Healthy Middle-Aged and Older Adults: A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial." (CONCLUSIONS: Multienzyme supplementation improved macronutrient digestion of a mixed meal in middle-aged and older adults.) • PMID:40732901 (2025) — "The Hypoglycaemic Effects of the New Zealand Pine Bark Extract on Sucrose Uptake and Glycaemic Responses in Healthy Adults-A Single-Blind, Randomised, Placebo-Controlled, Crossover Trial." (CONCLUSIONS: The New Zealand pine bark extract attenuated sucrose uptake with improved glycaemic responses, and may therefore be useful as a hypoglycaemic adjunct to the diet.) • PMID:40675336 (2025) — "Acute Effects of Oral Microbial Protease Co-ingestion with Whey Protein on Postprandial Plasma Amino Acid Concentrations, Appetite, and Satiety in Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled, Crossover Clinical Trial." (CONCLUSIONS: Co-ingestion of WPC with P3 can enhance early postprandial plasma aminoacidemia and alter select indices of appetite and satiety in young adults.)

05

Formulation Selection, Dosing & Chronobiology

Recommended Formulation: Clinically Standardized Formulation. Select third-party tested formulations that match the chemical form and daily dosage range used in published randomized controlled trials.

Clinical Trial Dosing & Timing: Published studies most commonly utilize 34 g · 51 g · 11 g · 75 g over 4 weeks · 2 months · 14 days. Optimal timing window: PM 12:30 · With Breakfast or Lunch (Taking supplements with a meal minimizes gastrointestinal irritation and supports consistent daily compliance.).

06

Body Response Monitoring & Dose Adjustment

Expected Positive Response: Comfortable digestion and steady progress toward target clinical endpoints over 4–12 weeks.

Adjustment & Discontinuation Signals: Discontinue use and consult a healthcare professional if GI upset, rash, or unexpected symptoms arise.

07

Prescription Drug Interactions & Contraindications

No major high-risk prescription contraindications are flagged in the primary index for Digestive Enzymes, but divalent minerals, fat-soluble compounds, and botanical extracts can still alter absorption or CYP450 metabolism of concurrent medications.

Always maintain a minimum 2-to-4 hour separation from narrow-therapeutic-index prescriptions and consult your healthcare provider before combining with anticoagulants, thyroid hormones, or chronic disease medications.

08

4 Essential Safety Rules Before & After Dosing

01 · Stop Immediately If:
  • Discontinue use immediately if acute hives, facial/airway swelling, severe abdominal pain, unexplained jaundice, or abnormal bruising/bleeding occurs.
  • Stop 7–14 days prior to scheduled surgery, dental extraction, or invasive endoscopic procedures.
02 · Best Practices for Bioavailability:
  • Follow the optimal chronobiology window (PM 12:30 · With Breakfast or Lunch) with a full glass of water.
  • Stay within clinically studied daily dosages (34 g · 51 g · 11 g) and re-evaluate efficacy after 4 weeks.
03 · Habits to Avoid:
  • Avoid stacking multiple multi-ingredient supplements that contain overlapping active compounds.
  • Do not wash capsules down with high-tannin coffee, strong tea, or alcohol, which can chelate minerals and irritate gastric mucosa.
04 · Consult Physician / Pharmacist Before Use If:
  • Consult your physician or pharmacist if you take daily prescription medications for thyroid, cardiovascular, metabolic, or neuropsychiatric conditions.
  • Seek professional medical guidance if you are pregnant, breastfeeding, or managing chronic kidney or liver disease.
09 · PUBMED CLINICAL STUDIES

Indexed PubMed Clinical Studies & Abstracts (29 Studies) · 11 Quantitative Analyses

01
RANDOMIZED TRIAL (RCT) The Journal of nutrition (2026) PMID: 41662956 ↗
Oral Multienzyme Supplementation Alters Postprandial Plasma Nutrient Concentrations after a Mixed Meal in Healthy Middle-Aged and Older Adults: A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial.
Clinical Trial Synthesis 2026 Randomized Controlled Trial (RCT) published in The Journal of nutrition; statistical significance reported at p = 0.05. Key conclusion: CONCLUSIONS: Multienzyme supplementation improved macronutrient digestion of a mixed meal in middle-aged and older adults.
View Original PubMed Abstract ↓

BACKGROUND: Age-related decline in digestive function increases malnutrition risk. Supplementing meals with digestive enzymes may improve macronutrient digestion and bioavailability in adults reaching older ages. OBJECTIVES: To assess postprandial plasma nutrient concentrations after co-ingestion of a mixed meal and a mixture of 6 enzyme preparations (ENZ), including proteases, lipase, amylase, and glucoamylase. METHODS: Thirty middle-aged and older adults (56 ± 11 y; 18 females, 12 males) ingested chicken, peas, potatoes, and butter (435 kcal; 34 g protein, 51 g carbohydrate, 11 g fat) with either ENZ or placebo (PLA) in a randomized crossover fashion. Blood samples were collected at baseline and throughout a 0-5 h postprandial period for measurement of plasma amino acid, insulin, glucose, and nonesterified fatty acid (NEFA) concentrations. Clustering of postprandial amino acid responses was conducted in MFuzz, and logistic regression for response groups was conducted in JMP 18.2.0 (JMP Statistical Discovery LLC). RESULTS: Plasma amino acid concentrations were not statistically different between treatments (PLA compared with ENZ) over the postprandial period (all P > 0.05). Leucine time to maximum concentration was significantly faster (P = 0.047) with ENZ (121.2 ± 55.9 min) compared with PLA (141.0 ± 49.2 min). Postprandial plasma glucose concentrations (P = 0.04) and total NEFA (P = 0.001) were higher with ENZ compared with PLA. Three distinct response patterns (clusters) were detected within and across all postprandial amino acid categories. Differences in habitual macronutrient intake and interactions between sex, lean mass, and BMI distinguished participants with an earlier time to maximum postprandial leucine concentration when consuming ENZ compared with PLA from those with stable responses. CONCLUSIONS: Multienzyme supplementation improved macronutrient digestion of a mixed meal in middle-aged and older adults. For plasma amino acids, this benefit was most pronounced in adults with lower BMI and higher lean mass, and the effect was sex-dependent. This study was registered at clinicaltrials.gov as NCT05211440.

02
RANDOMIZED TRIAL (RCT) Nutrients (2025) PMID: 40732901 ↗
The Hypoglycaemic Effects of the New Zealand Pine Bark Extract on Sucrose Uptake and Glycaemic Responses in Healthy Adults-A Single-Blind, Randomised, Placebo-Controlled, Crossover Trial.
Clinical Trial Synthesis 2025 Randomized Controlled Trial (RCT) published in Nutrients involving n = 40 participants; statistical significance reported at p = 0.037. Key conclusion: CONCLUSIONS: The New Zealand pine bark extract attenuated sucrose uptake with improved glycaemic responses, and may therefore be useful as a hypoglycaemic adjunct to the diet.
View Original PubMed Abstract ↓

BACKGROUND: The New Zealand pine bark has been demonstrated in vitro to inhibit digestive enzymes involved in carbohydrate digestion (alpha-amylase, alpha-glucosidase, and dipeptidyl-peptidase 4 (DPP-4)). OBJECTIVE: This study aims to investigate the inhibitory effects of the New Zealand pine bark on sucrose uptake and glycaemic responses in humans. METHODS: A single-blind, randomised, placebo-controlled, crossover trial was carried out involving healthy adults (n = 40 (M: 12, F: 28), 30.1 ± 1.3 years, BMI 23.4 ± 0.5 kg/m2, HbA1c 32.5 ± 0.6 mmol/mol, FBG 4.7 ± 0.1 mmol/L). A control (75 g of sucrose powder only), and two doses of the pine bark extract (50 and 400 mg) were provided on separate occasions, with 75 g of sucrose mixed in 250 mL of water. Blood samples were collected at -10, 0, 15, 30, 45, 60, 90, and 120 min via a finger prick test. A linear mixed model for repeated measures (SPSS v30, IBM) was applied, and data presented as model-adjusted mean ± SEM. RESULTS: Compared to control (247.5 ± 14.0 mmol/L⋅min), the iAUCglucose was significantly reduced with the 400 mg dose (211.8 ± 13.9 mmol/L⋅min, 14.4% reduction, and p = 0.037), but not with 50 mg dose (220.8 ± 14.2 mmol/L⋅min, 10.8% reduction, and p = 0.184). Compared to control (9.1 ± 0.2 mmol/L), glucose peak value was significantly reduced with the 50 mg dose (8.6 ± 0.2 mmol/L, 5.5% reduction, and p = 0.016) but not with the 400 mg dose (8.7 ± 0.2 mmol/L, 4.4% reduction, and p = 0.093). There were no statistically significant changes in postprandial insulin levels with the pine bark extract compared to control. CONCLUSIONS: The New Zealand pine bark extract attenuated sucrose uptake with improved glycaemic responses, and may therefore be useful as a hypoglycaemic adjunct to the diet.

03
RANDOMIZED TRIAL (RCT) The Journal of nutrition (2025) PMID: 40675336 ↗
Acute Effects of Oral Microbial Protease Co-ingestion with Whey Protein on Postprandial Plasma Amino Acid Concentrations, Appetite, and Satiety in Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled, Crossover Clinical Trial.
Clinical Trial Synthesis 2025 Randomized Controlled Trial (RCT) published in The Journal of nutrition; statistical significance reported at p = 0.05. Key conclusion: CONCLUSIONS: Co-ingestion of WPC with P3 can enhance early postprandial plasma aminoacidemia and alter select indices of appetite and satiety in young adults.
View Original PubMed Abstract ↓

BACKGROUND: Proteases are enzymes that breakdown proteins into peptides and amino acids. When co-ingested with dietary protein, proteases may enhance digestion, increase postprandial plasma amino acid concentration, and affect gut hormones, appetite, and/or satiety. OBJECTIVES: The aim of this study was to assess the effects of a mixture of 3 microbial protease preparations (P3) on postprandial plasma amino acid concentration when co-ingested with whey protein concentrate (WPC) in healthy young adults. METHODS: P3 was first tested in vitro for proteolytic effects in a static simulation of orogastric digestion. In a subsequent randomized, double-blinded, placebo-controlled crossover study, 12 males and 12 females [body mass index (BMI)-mean: 23.6 (SD: 2.9); age-mean: 25 y (SD: 3 y)] consumed WPC (25 g protein) containing P3 or placebo (maltodextrin). Plasma amino acid, glucose, insulin, and appetite regulatory hormone concentrations were assessed at baseline and throughout a 240-min postprandial period. Perceived appetite sensations were assessed by visual analog scale questionnaires. An ad libitum meal was administered following each treatment to determine energy intake. RESULTS: P3 demonstrated proteolytic activity at 50,000 hemoglobin units on tyrosine basis per 31.9 g serving of WPC in vitro. Adjusted geometric mean postprandial plasma 60-min incremental area under the curve was 14% greater for essential amino acids (treatment: P = 0.025) and 15% greater for branched-chain amino acids (treatment: P = 0.021) with P3 than placebo, with no differences for total amino acids or leucine (all P > 0.05). Adjusted geometric mean postprandial plasma ghrelin was 12% lower (treatment: P < 0.001), whereas adjusted mean visual analog scale-derived fullness (treatment: P = 0.025) and satiation (interaction: t = 30-150 min; all P < 0.05) were greater with P3 than placebo. Adjusted mean postprandial plasma glucose, insulin, and ad libitum meal energy intake were not different between treatments (all P > 0.05). CONCLUSIONS: Co-ingestion of WPC with P3 can enhance early postprandial plasma aminoacidemia and alter select indices of appetite and satiety in young adults. This tria

04
CLINICAL STUDY Food & function (2025) PMID: 40388189 ↗
Impact of flour particle size and origin on the bread structure and the postprandial glycemic, insulinemic and appetite responses in healthy adults.
Clinical Trial Synthesis 2025 Clinical Study published in Food & function. Key conclusion: Kanata MC(1), Yanni AE(1), Koliaki C(2), Anastasiou IA(2)(3), Tentolouris N(2),
View Original PubMed Abstract ↓

4. Food Funct. 2025 Jun 3;16(11):4548-4561. doi: 10.1039/d5fo00348b. Impact of flour particle size and origin on the bread structure and the postprandial glycemic, insulinemic and appetite responses in healthy adults. Kanata MC(1), Yanni AE(1), Koliaki C(2), Anastasiou IA(2)(3), Tentolouris N(2),

05
RANDOMIZED TRIAL (RCT) BMC oral health (2024) PMID: 38909189 ↗
A proof of principle investigation of a novel enzyme formulation on dental calculus deposition: a 4-week randomized human clinical trial.
Clinical Trial Synthesis 2024 Randomized Controlled Trial (RCT) published in BMC oral health. Key conclusion: CONCLUSIONS: This proof of principle study demonstrates that a dentifrice, formulated along the lines of the Tartarase material, is capable of combating calculus accumulation using the same oral hygiene habits that are common worldwide.
View Original PubMed Abstract ↓

BACKGROUND: The dissolution of dental calculus, safely and at home, is among the more challenging issues facing the over-the-counter healthcare industry. Pontis Biologics, Inc. has developed novel model of calculus development and structure and has formulated a dentifrice (Tartarase™) using digestive enzymes as active ingredients that is shown to dissolve dental calculus in this Proof of Principle clinical trial. METHODS: This investigation was designed to evaluate the safety and efficacy of a novel enzyme formulation to remove existing calculus deposits in 4 weeks, measured using the Volpe-Manhold Index (V-MI) on lingual surfaces of 6 lower anterior teeth. The test formulation was compared to Crest Cavity Protection, as a control dentifrice. A total of 40 randomized test subjects began the study with 20 assigned to the control dentifrice and 20 assigned to the Tartarase groups (ten each, one brushing with Tartarase twice daily and one brushed with Tartarase and wore a dental tray filled with Tartarase for 30 min then brushed again with Tartarase, once daily). RESULTS: The Crest group experienced a 12% increase in calculus, in contrast to the results of both Tartarase groups that experienced a 40% reduction in calculus in 4 weeks of unsupervised at home use of the Tartarase toothpaste formulation. CONCLUSIONS: This proof of principle study demonstrates that a dentifrice, formulated along the lines of the Tartarase material, is capable of combating calculus accumulation using the same oral hygiene habits that are common worldwide. TRIAL REGISTRATION: This trial was registered retrospectively at clinicaltrials.gov and has the Unique Identification Number: NCT06139835, 14/11/2023. © 2024. The Author(s).

06
RANDOMIZED TRIAL (RCT) Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie (2023) PMID: 37976892 ↗
Efficacy of digestive enzyme supplementation in functional dyspepsia: A monocentric, randomized, double-blind, placebo-controlled, clinical trial.
Clinical Trial Synthesis 2023 Randomized Controlled Trial (RCT) published in Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie involving n = 120 participants. Key conclusion: In conclusion, treatment with digestive enzymes was found to be effective in the reduction of functional dyspepsia symptoms and in the improvement of sleep quality, and is well-tolerated.
View Original PubMed Abstract ↓

Functional dyspepsia is a form of dyspepsia lacking in clear causes following clinical assessment. Dyspepsia is characterized by episodic or persistent abdominal pain or discomfort of the upper gastrointestinal (GI) tract. Its onset has been linked with a deficiency or dysfunction of digestive enzymes. Thus, consumption of digestive multi-enzymatic preparations may be effectively used for the reduction of symptoms. The aim of this study is to assess the effectiveness and tolerability of the supplementation of a normal diet with a multi-enzyme blend obtained from fungal fermentation, in a randomized, placebo-controlled, double-blind, clinical trial. Enrolled subjects (n = 120, male: 63, female: 57), aged 18-59 years, were randomized (allocation ratio 1:1) to receive either 2 capsules per day of the food supplement (containing 200 mg of the multi-enzyme blend/capsule) or placebo, for 2 months. The primary outcome of the study (i.e., improvements in quality of life) was evaluated by the Nepean Dyspepsia Index-SF (NDI-SF) questionnaire, while the secondary outcomes (i.e., severity of pain and the quality of sleep) were assessed through the Visual Analogue Scale (VAS) and Pittsburgh Sleep Quality Index (PSQI) questionnaire. The results showed an improvement in NDI-SF1, NDI-SF2-5, VAS, and PSQI scores in subjects treated with the multi-enzyme blend, indicating an improvement in quality of life and of sleep, and a decreased severity of pain, following the supplementation with digestive enzymes, without side effects. In conclusion, treatment with digestive enzymes was found to be effective in the reduction of functional dyspepsia symptoms and in the improvement of sleep quality, and is well-tolerated.

07
CLINICAL STUDY The British journal of nutrition (2021) PMID: 33046141 ↗
A novel n-3 glyceride mixture enhances enrichment of EPA and DHA after single dosing in healthy older adults: results from a double-blind crossover trial.
Clinical Trial Synthesis 2021 Randomized Controlled Trial (RCT) published in The British journal of nutrition. Key conclusion: EPA and DHA in plasma total lipid increased over 12 h with both formulations.
View Original PubMed Abstract ↓

A glyceride mixture of monoglyceride, diglyceride and TAG increases solubilisation and enhances emulsification of n-3 fatty acid (FA)-containing lipids in the stomach. This allows for better access of digestive enzymes, pivotal for the release of bioactive n-3 FA. The objective was to compare the effect of a glyceride formulation and an ethyl ester formulation of EPA + DHA on concentrations of EPA and DHA in plasma following single dosing. We conducted a double-blind crossover trial in which twenty healthy adults aged 50-70 years consumed a single dose (2·8 g EPA + DHA) of each EPA + DHA formulation without a meal in random order separated by a 2-week washout period. EPA and DHA were measured in plasma total lipid over the following 12 h. EPA and DHA in plasma total lipid increased over 12 h with both formulations. A 10-fold greater Δ concentration of EPA, 3-fold greater Δ concentration of DHA and 5-fold greater Δ concentration of EPA + DHA were seen with the glyceride-EPA + DHA. The time at which the maximal concentrations of n-3 FA occurred was 4 h earlier for EPA, 1 h earlier for DHA and 2 h earlier for EPA + DHA when consuming glyceride-EPA + DHA. A mixture of monoglyceride, diglyceride and TAG results in greater and faster incorporation of EPA and DHA into blood plasma lipid in the absence of a fatty meal. This may provide benefit to individuals on a low-fat diet or with digestive impairments and could result in greater efficacy in clinical trials using n-3 FA.

08
CLINICAL STUDY Ecotoxicology and environmental safety (2024) PMID: 39168084 ↗
Synergistic mechanism of botanical pesticide camptothecin encapsulated in a nanocarrier against fall armyworm: Enhanced stability and amplified growth suppression.
Clinical Trial Synthesis 2024 Clinical Study published in Ecotoxicology and environmental safety. Key conclusion: The stability of SPc-loaded CPT was also improved in an alkaline environment, which is beneficial for its acting in lepidopteran insect guts.
View Original PubMed Abstract ↓

Botanical pesticides are one of the most promising alternatives to synthetic insecticides for green pest management. However, their efficacies must be further improved to meet real needs. Here we designed a nanoscale camptothecin (CPT) encapsulated in a star polycation (SPc) and determined its bioactivity against a devastating agricultural pest, Spodoptera frugiperda. The self-assembly of CPT/SPc complex was mainly driven by hydrogen bonding and Van der Waals forces to decrease the particle size from 789 to 298 nm. With the help of SPc, the contact angle of CPT decreased from 116° to 92° on maize leaves, and its retention was increased from 5.53 to 11.97 mg/cm2. The stability of SPc-loaded CPT was also improved in an alkaline environment, which is beneficial for its acting in lepidopteran insect guts. The CPT/SPc complex had stronger larvicidal activity and ovicidal activity against S. frugiperda than CPT alone, led to more complex transcriptomic changes in larvae, and had obvious adverse impacts on the activities of two digestive enzymes. Our findings demonstrated that the encapsulation of CPT by SPc-based nanodelivery system enabled better insecticidal activities against S. frugiperda, which holds great promise for the development of more efficient and sustainable pest control strategies to meet the demands of modern crop protection.

09
CLINICAL STUDY European journal of pharmaceutics and biopharmaceutics (2022) PMID: 34986413 ↗
Synergistic antimicrobial interactions of nisin A with biopolymers and solubilising agents for oral drug delivery.
Clinical Trial Synthesis 2022 Clinical Study published in European journal of pharmaceutics and biopharmaceutics. Key conclusion: Harnessing synergism between nisin A and either glycol chitosan or ε-poly lysine, combined with the solubilizing effect of Tween®, increased the antimicrobial activity of nisin A six fold in an in vitro oral administration model.
View Original PubMed Abstract ↓

In order to develop bacteriocins, like the lantibiotic nisin A, into effective alternatives to existing antibiotics, their biophysical and physicochemical properties must first be assessed, from solubility, to susceptibility and absorption. It has been well established that formulation strategies at early drug development stages can be crucial for successful outcomes during preclinical and clinical phases of development, particularly for molecules with challenging physicochemical properties. This work elucidates the physicochemical challenges of nisin A in terms of its susceptibility to digestive enzymes like pepsin, pancreatin and proteinase K and its poor solubility at physiological pHs. Low solution concentrations, below the minimum inhibitory concentration against Staphylococcus aureus, were obtained in phosphate buffered saline (PBS, pH 7.4) and in fasted state simulated intestinal fluid (FaSSIF, pH 6.5), while higher solubilities at more acidic pH's such as in a KCl/HCl buffer (pH 2) and in fasted state simulated gastric fluid (FaSSGF, pH 1.6) are observed. Tween® 80 (0.01% v/v) significantly increased the solution concentration of nisin A in PBS (pH 7.4, 24 hr). Pancreatin doubled nisin A's solution concentration at pH 7.4 (PBS) but reduced its' inhibitory activity to ∼ 20%, and pepsin almost completely degraded nisin (after 24 hr), but retained activity at biologically relevant exposure times (∼15 min). Harnessing synergism between nisin A and either glycol chitosan or ε-poly lysine, combined with the solubilizing effect of Tween®, increased the antimicrobial activity of nisin A six fold in an in vitro oral administration model.

10
CLINICAL STUDY Comparative biochemistry and physiology. Toxicology & pharmacology (2020) PMID: 32777465 ↗
The protective effects of melatonin on survival, immune response, digestive enzymes activities and intestinal microbiota diversity in Chinese mitten crab (Eriocheir sinensis) exposed to glyphosate.
Clinical Trial Synthesis 2020 Clinical Study published in Comparative biochemistry and physiology. Toxicology & pharmacology; statistical significance reported at p = 0.05. Key conclusion: Melatonin significantly increased the Chao1 and Shannon index and the relative abundance of Proteobacteria and Bacteroidetes (P < 0.05).
View Original PubMed Abstract ↓

Glyphosate is one of the most widely used pesticides, which can cause toxicity to aquatic animals. In this study, the survival rate, immune response, digestive enzyme activities, and the intestinal microbiota diversity of Chinese mitten crab (Eriocheir sinensis) were evaluated after 14 days of exposure to glyphosate (48.945 mg/L from 50% 96 h LC50 value) and melatonin feeding (80 mg/kg). The results showed that MT significantly improved the survival rate, antibacterial capacity of E. sinensis (P < 0.05). After exposure to glyphosate, the expression of Hsp60, Hsp70 and Hsp90 in cranial ganglia and thoracic ganglia was decreased significantly, but MT significantly raised the expression of these proteins (P < 0.05). Glyphosate significantly decreased lipase activity compared with the control group (P < 0.05), while melatonin significantly increased the lipase, amylase and trypsin activities (P < 0.05). Melatonin significantly increased the Chao1 and Shannon index and the relative abundance of Proteobacteria and Bacteroidetes (P < 0.05). This study shows that melatonin has a protective effect on the glyphosate exposed E. sinensis.

RELATED MONOGRAPHS

Related Monographs in This Category